CN106966984A - The preparation method of eltrombopag olamine diethanolamine salt - Google Patents
The preparation method of eltrombopag olamine diethanolamine salt Download PDFInfo
- Publication number
- CN106966984A CN106966984A CN201710212131.XA CN201710212131A CN106966984A CN 106966984 A CN106966984 A CN 106966984A CN 201710212131 A CN201710212131 A CN 201710212131A CN 106966984 A CN106966984 A CN 106966984A
- Authority
- CN
- China
- Prior art keywords
- eltrombopag olamine
- diethanolamine salt
- monoethanolamine
- 30min
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
Abstract
The invention provides a kind of preparation method of eltrombopag olamine diethanolamine salt, the method is simple to operate, is adapted to industrialized production；And eltrombopag olamine diethanol amine salt bulk drug prepared by the method meets ICH guidelines.
Description
Technical field
The invention belongs to the preparing technical field of eltrombopag olamine diethanolamine salt.
Background technology
Eltrombopag olamine piece (Promacta) listing of U.S. FDA approval on November 20th, 2008 GlaxoSmithKline PLC company,
For treating through glucocorticoid medicine, immunoglobulin therapy be invalid or Postsplenectomy chronic idiopathic decrease of platelet
The decrease of platelet of property purpura (ITP) patient.
Eltrombopag olamine is that the first oral non-peptides thrombopoietin receptor for being approved to treat Adult chronic ITP patient swashs
Dynamic agent, preclinical and clinical studies show stimulate this product can increased platelets counts bone marrow megakaryocyte hyperplasia and differentiation.Its batch
Quasi- treatment ITP patient is an important milestone.
Eltrombopag olamine diethanolamine salt chemistry is entitled：3 '-[(2Z)-[1- (3,4- 3,5-dimethylphenyls) -1,5- dihydro -3- first
Base -5- oxo -4H- pyrazoles -4- subunits] diazanyl] -2 '-hydroxyl-[1,1 '-xenyl] -3- carboxylic acids two-(MEA) structure
Formula is as follows：
Due to eltrombopag olamine free acid very low, the only 5 μ g/ml of water solubility, it is unfavorable for the absorption of compound in vivo, reduces
Bioavilability.
Yuan Yan companies GlaxoSmithKline PLC reports in patent CN100542530C eltrombopag olamine being prepared into eltrombopag olamine two
Solubility reaches in ethanolamine salt, it is possible to increase solubility of the eltrombopag olamine in water, eltrombopag olamine diethanol amine salt solution
14.2mg/ml, so as to improve the bioavilability of eltrombopag olamine in vivo.
The method for preparing eltrombopag olamine diethanolamine salt of patent CN100542530C reports, with ethanol or tetrahydrofuran or
Their mixture is as solvent, at room temperature into salt, and obtained eltrombopag olamine diethanolamine salt dissolvent residual is unqualified.
When using ethanol for solvent, by under the eltrombopag olamine counterflow condition being dissolved in tetrahydrofuran, while ethanol is steamed, side
Tetrahydrofuran mode is added dropwise into salt, obtained eltrombopag olamine diethanolamine salt, dissolvent residual tetrahydrofuran 0.05%（Limit：
0.072%）Close to limit, but such a method complex operation, be not suitable for industrialized production.The experimental data specifically reported is as follows
Table：
The content of the invention
The purpose of the present invention is that solution prepares eltrombopag olamine diethanolamine salt, and dissolvent residual is unqualified, and uncomfortable
This technical problem of conjunction industrialized production.There is provided it is a kind of it is new be suitable for industrialized eltrombopag olamine diethanol amine preparation method,
The eltrombopag olamine diethanolamine salt dissolvent residual prepared in this way meets Chinese Pharmacopoeia standard.
To reach above-mentioned purpose, the technical scheme that the present invention takes is as follows：
(a) eltrombopag olamine free alkali is added in solvent and stirred；
Step (a）In used solvent be selected from ether, isopropyl ether, methyl tertiary butyl ether(MTBE), ethyl acetate, n-propyl acetate, acetic acid
Isopropyl ester, n-butyl acetate, isobutyl acetate, tert-butyl acetate, acetone, butanone, dichloromethane, chloroform, 1,2- dichloroethanes,
One kind or any mixture in acetonitrile or isopropanol；
(b) a certain amount of monoethanolamine is added in above-mentioned reaction, and salt is carried out into stirring certain time under certain temperature；
Step (b）In monoethanolamine consumption be：Monoethanolamine：Eltrombopag olamine free alkali（Mol ratio）=2.1~20；
(c) by above-mentioned reacting liquid filtering, filter cake wet product eltrombopag olamine diethanolamine salt is obtained；
(d) wet product Ai Qu pool handkerchief diethanolamine salts are dried；
Drying in step (d) can be vacuum drying or heated-air drying, and drying temperature is 30 DEG C ~ 80 DEG C, and drying time is 1
Hour ~ 48 hours.
Brief description of the drawings
Fig. 1 eltrombopag olamine diethanolamine salt XRPD collection of illustrative plates.
Embodiment
Embodiment 1
By eltrombopag olamine free alkali（50g, 113mmol）, ethyl acetate 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（69g, 1.13mol）, 30 ± 5 DEG C of stir about 30min are reacted on, are filtered, filter cake is in 50 ± 5 DEG C of hot blasts
Dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63.2g.Yield：99%, purity：99.8%, dissolvent residual：0.06%（Acetic acid
Ethyl ester）.The eltrombopag olamine diethanolamine salt of preparation is crushed according to formulation requirements.Fig. 1 eltrombopag olamine diethanolamine salts
XRPD collection of illustrative plates.
Embodiment 2
By eltrombopag olamine free alkali（50g, 113mmol）, ethyl acetate 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（14.5g, 237mmol）, react and be heated to return stirring about 30min, filter, filter cake is in 30 ± 5 DEG C
Vacuum drying about 24 hours, obtains eltrombopag olamine diethanolamine salt 63g.Yield：98.7%, purity：99.3%, dissolvent residual：0.04%
（Ethyl acetate）.
Embodiment 3
By eltrombopag olamine free alkali（50g, 113mmol）, ethyl acetate 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（138g, 2.26mol）, react on 35 ± 5 DEG C of stir abouts 2 hours, filtering, filter cake is in 80 ± 5 DEG C of warm
Air-dry dry about 1 hour, obtain eltrombopag olamine diethanolamine salt 63.2g.Dissolvent residual：0.14%（Ethyl acetate）.
Embodiment 4
By eltrombopag olamine free alkali（50g, 113mmol）, ethyl acetate 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（27.6g, 452mol）, 0 ± 5 DEG C of stir about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of vacuum
Dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63.2g.Dissolvent residual：0.17%（Ethyl acetate）.
Embodiment 5
By eltrombopag olamine free alkali（50g, 113mmol）, methanol 500ml is added in reaction bulb in 25 ± 5 DEG C of stir about 30min,
Add monoethanolamine（27.6g, 452mol）, stirred at reflux about 60min is reacted on, is filtered, filter cake is dried in vacuo about in 50 ± 5 DEG C
3 hours, obtain eltrombopag olamine diethanolamine salt 58g.Dissolvent residual：0.25%（Methanol）.
Embodiment 6
By eltrombopag olamine free alkali（50g, 113mmol）, isopropanol 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（27.6g, 452mol）, stirred at reflux about 60min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of vacuum
Dry about 1 hour, obtain eltrombopag olamine diethanolamine salt 57g.Dissolvent residual：0.48%（Isopropanol）.
Embodiment 7
By eltrombopag olamine free alkali（50g, 113mmol）, acetone 500ml is added in reaction bulb in 25 ± 5 DEG C of stir about 30min,
Add monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is small in 50 ± 5 DEG C of heated-air dryings 3
When, obtain eltrombopag olamine diethanolamine salt 52g.Dissolvent residual：0.27%（Acetone）.
Embodiment 8
By eltrombopag olamine free alkali（50g, 113mmol）, butanone 500ml is added in reaction bulb in 25 ± 5 DEG C of stir about 30min,
Add monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of heated-air dryings about 3
Hour, obtain eltrombopag olamine diethanolamine salt 61g.Dissolvent residual：0.17%（Butanone）.
Embodiment 9
By eltrombopag olamine free alkali（50g, 113mmol）, ether 500ml is added in reaction bulb in 25 ± 5 DEG C of stir about 30min,
Add monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of heated-air dryings about 3
Hour, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.05%（Ether）.
Embodiment 10
By eltrombopag olamine free alkali（50g, 113mmol）, isopropyl ether 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of hot blasts
Dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.08%（Isopropyl ether）.
Embodiment 11
By eltrombopag olamine free alkali（50g, 113mmol）, methyl tertiary butyl ether(MTBE) 500ml, be added in reaction bulb in 25 ± 5 DEG C stirring
About 30min, adds monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of warm
Air-dry dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.08%（Methyl tertiary butyl ether(MTBE)）.
Embodiment 12
By eltrombopag olamine free alkali（50g, 113mmol）, n-propyl acetate 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of hot blasts
Dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.12%（N-propyl acetate）.
Embodiment 13
By eltrombopag olamine free alkali（50g, 113mmol）, isopropyl acetate 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of hot blasts
Dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.08%（Isopropyl acetate）.
Embodiment 14
By eltrombopag olamine free alkali（50g, 113mmol）, n-butyl acetate 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of hot blasts
Dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.18%（N-butyl acetate）.
Embodiment 15
By eltrombopag olamine free alkali（50g, 113mmol）, isobutyl acetate 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of hot blasts
Dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.22%（Isobutyl acetate）.
Embodiment 16
By eltrombopag olamine free alkali（50g, 113mmol）, tert-butyl acetate 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of hot blasts
Dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.11%（Tert-butyl acetate）.
Embodiment 17
By eltrombopag olamine free alkali（50g, 113mmol）, dichloromethane 500ml is added in reaction bulb in 25 ± 5 DEG C of stir abouts
30min, adds monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of hot blasts
Dry about 3 hours, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.09%（Dichloromethane）.
Embodiment 18
By eltrombopag olamine free alkali（50g, 113mmol）, chloroform 500ml is added in reaction bulb in 25 ± 5 DEG C of stir about 30min,
Add monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of heated-air dryings about 3
Hour, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.02%（Chloroform）.
Embodiment 19
By eltrombopag olamine free alkali（50g, 113mmol）, acetonitrile 500ml is added in reaction bulb in 25 ± 5 DEG C of stir about 30min,
Add monoethanolamine（69g, 1.13mol）, stirred at reflux about 30min is reacted on, is filtered, filter cake is in 50 ± 5 DEG C of heated-air dryings about 3
Hour, obtain eltrombopag olamine diethanolamine salt 63g.Dissolvent residual：0.01%（Acetonitrile）.
Above example is construed as, and those skilled in the art can be entered based on content disclosed herein to the present invention
The various various modifications and improvements without departing from spirit and scope of the invention of row.They should all fall in claims hereof
In the scope of patent protection of definition.Moreover, it will be appreciated that embodiment provided herein is merely to illustrate the purpose of the present invention, and
It should not be construed as limitation of the present invention.
Claims (7)
1. a kind of preparation method of eltrombopag olamine diethanolamine salt, comprises the following steps：
(a) eltrombopag olamine free alkali is added in solvent and stirred；
Step (a）In used solvent be selected from ether, isopropyl ether, methyl tertiary butyl ether(MTBE), ethyl acetate, n-propyl acetate, acetic acid
Isopropyl ester, n-butyl acetate, isobutyl acetate, tert-butyl acetate, acetone, butanone, dichloromethane, chloroform, acetonitrile or isopropanol
In one kind or any number of mixture；
(b) a certain amount of monoethanolamine is added in above-mentioned reaction, and salt is carried out into stirring certain time under certain temperature；
(c) by above-mentioned reacting liquid filtering, filter cake wet product eltrombopag olamine diethanolamine salt is obtained；
(d) wet product Ai Qu pool handkerchief diethanolamine salts are dried.
2. the method according to claim 1, it is characterised in that in step (b）In monoethanolamine consumption be：Monoethanolamine:Chinese mugwort
Bent ripple handkerchief free alkali（Mol ratio）=2.1:1~20:1, preferably 2.5:1~10:1, most preferably 2.5:1~4.0:1.
3. the method according to claim 1, it is characterised in that in step (b）Middle signified reaction temperature is 0 DEG C ~ 100
DEG C, preferably 15 DEG C ~ 40 DEG C, most preferably 30 DEG C ~ 35 DEG C.
4. the method according to claim 1, it is characterised in that the drying mode in step (d) be selected from vacuum drying or
Person's heated-air drying.
5. the method according to claim 1, it is characterised in that the drying temperature in step (d) is 30 DEG C ~ 80 DEG C, is done
The dry time is 1 hour ~ 24 hours.
6. the method according to claim 1, it is characterised in that in step (d）Also include step afterwards（e）
Step（e）Dried eltrombopag olamine di-methylcarbinol amine salt is crushed.
7. the method according to claim 1, it is characterised in that in step (a）In used solvent ethyl acetate,
One kind or any number of mixture in butanone, acetone, methyl tertiary butyl ether(MTBE), most preferably ethyl acetate or isopropyl ether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710212131.XA CN106966984A (en) | 2017-04-01 | 2017-04-01 | The preparation method of eltrombopag olamine diethanolamine salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710212131.XA CN106966984A (en) | 2017-04-01 | 2017-04-01 | The preparation method of eltrombopag olamine diethanolamine salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106966984A true CN106966984A (en) | 2017-07-21 |
Family
ID=59336815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710212131.XA Pending CN106966984A (en) | 2017-04-01 | 2017-04-01 | The preparation method of eltrombopag olamine diethanolamine salt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106966984A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107915678A (en) * | 2017-08-30 | 2018-04-17 | 孙婷婷 | A kind of preparation method for the medicine eltrombopag olamine for being used to treat Idiopathic Thrombocytopenic Purpura |
| CN111718297A (en) * | 2019-03-18 | 2020-09-29 | 武汉武药科技有限公司 | Eltrombopag diethanolamine salt and preparation method thereof |
| WO2022071896A1 (en) * | 2020-09-30 | 2022-04-07 | Deva Holding | Eltrombopag novel salts |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1652842A (en) * | 2002-05-22 | 2005-08-10 | 史密丝克莱恩比彻姆公司 | 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- 1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| US20110196008A1 (en) * | 2009-04-01 | 2011-08-11 | Pliva Hrvatska D.O.O. | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof |
| WO2013072921A2 (en) * | 2011-09-13 | 2013-05-23 | Glenmark Generics Limited | Process for preparation of substituted 3'-hydrazino-biphenyl-3-carboxylic acid compounds |
| CN104844582A (en) * | 2015-04-24 | 2015-08-19 | 江苏恒瑞医药股份有限公司 | Crystal form of diethanolamine salt of thrombopoietin mimic and preparation method thereof |
-
2017
- 2017-04-01 CN CN201710212131.XA patent/CN106966984A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1652842A (en) * | 2002-05-22 | 2005-08-10 | 史密丝克莱恩比彻姆公司 | 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- 1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| US20110196008A1 (en) * | 2009-04-01 | 2011-08-11 | Pliva Hrvatska D.O.O. | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof |
| CN102448942A (en) * | 2009-04-01 | 2012-05-09 | 普利瓦赫尔瓦茨卡有限公司 | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof |
| WO2013072921A2 (en) * | 2011-09-13 | 2013-05-23 | Glenmark Generics Limited | Process for preparation of substituted 3'-hydrazino-biphenyl-3-carboxylic acid compounds |
| CN104844582A (en) * | 2015-04-24 | 2015-08-19 | 江苏恒瑞医药股份有限公司 | Crystal form of diethanolamine salt of thrombopoietin mimic and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107915678A (en) * | 2017-08-30 | 2018-04-17 | 孙婷婷 | A kind of preparation method for the medicine eltrombopag olamine for being used to treat Idiopathic Thrombocytopenic Purpura |
| CN111718297A (en) * | 2019-03-18 | 2020-09-29 | 武汉武药科技有限公司 | Eltrombopag diethanolamine salt and preparation method thereof |
| WO2022071896A1 (en) * | 2020-09-30 | 2022-04-07 | Deva Holding | Eltrombopag novel salts |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105237571B (en) | The salt of 9 [(R) 2 [[(S) [[(S) 1 (isopropoxy carbonyl) ethyl] amino] phenoxy group phosphinyl] methoxyl group] propyl group] adenines | |
| CN106966984A (en) | The preparation method of eltrombopag olamine diethanolamine salt | |
| CN104230924B (en) | A kind of synthetic method of moxifloxacin hydrochloride | |
| CN111943932B (en) | 3-pyridine sulfonyl-1-N-hetero pyrrole derivative capable of treating peptic ulcer and preparation method and application thereof | |
| CN106674176B (en) | 7-substituted-4-aryl coumarin compound and preparation method and application thereof | |
| CN103012382B (en) | A kind of preparation method of olmesartan medoxomil | |
| AU2016246068A1 (en) | Xanthine-substituted alkynyl carbamates/reverse carbamates as A2b antagonists | |
| CN103145636B (en) | 1,4-diacyl-3,6-diphenyl-1,4-dihydrotetrazine compound as well as preparation method and application thereof | |
| CN102260260A (en) | 8-phenyl xanthine compound, preparation method, medicine composition including the compound and purpose thereof | |
| CN113233975B (en) | Preparation method of bevacizidine acid | |
| CN105085612A (en) | N-(2)-L-alanyl-L-glutamine compound prepared by adopting particle crystal form optimization technique and preparation thereof | |
| CN107445935A (en) | A kind of hesperetin analog derivative of amide groups substitution and its preparation and as the application in the medicine of anti-inflammatory | |
| CN107698484B (en) | Preparation method and application of lenalidomide derivative | |
| CN111548310B (en) | Levosimendan sodium crystal form and preparation method thereof | |
| CN107235973A (en) | The preparation method of the adjoining fluorobenzene calcium composition of piperidones chain with pharmaceutical activity | |
| TW200306307A (en) | Novel crystal form of 5-hydroxy-1-methylhydantoin | |
| CN113354647A (en) | Ganciclovir sodium synthesis process | |
| CN106674206A (en) | Eutectic drug for treating heart failure | |
| CN104211693B (en) | Rivaroxaban crystalline form, preparation method and application | |
| CN103086956B (en) | A kind of purification process of clevidipine butyrate intermediate | |
| CN110872292B (en) | A route for synthesizing linagliptin as diabetes medicine | |
| CN107382941B (en) | Flavone derivative and preparation method and application thereof | |
| CN114805369B (en) | 2, 6-disubstituted purine compounds, preparation method and application thereof | |
| CN112110902B (en) | 1-deoxynojirimycin-kaempferol compound, intermediate, preparation method and application | |
| CN110759848A (en) | Ethanesulfonic acid nintedanib impurity as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170721 |